SEAGEN INC. news, videos and press releases
For more news please use our advanced search feature.
SEAGEN INC. - More news...
SEAGEN INC. - More news...
- J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board
- Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
- Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
- Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
- Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
- Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
- Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
- Seagen Stockholders Approve Acquisition by Pfizer
- Seagen Reports First Quarter 2023 Financial Results
- SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
- Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
- SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
- Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
- FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
- Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
-
“The Buzz'' Show: Pfizer (NYSE: PFE) to Acquire Seagen Inc. for USD 43 Billion
- SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.
- STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Seagen, Inc. - SGEN
- SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Seagen Inc.
- Shareholder Alert: Ademi LLP investigates whether Seagen Inc. has obtained a Fair Price in its transaction with Pfizer
- SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
- Pfizer Invests $43 Billion to Battle Cancer
- Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
- Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
- Seagen to Present at the Cowen 43rd Annual Health Care Conference
- U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen
- Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
- Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
- Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
